Abstract Introduction Plaque psoriasis (PsO), characterized by demarcated, erythematous,
scaly skin, can have a substantial negative impact on patients' quality of life. This …

Abstract Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has
substantial negative impact on patients' quality of life. Secukinumab, an approved treatment …

Secukinumab is effective in treating patients with moderate‐to‐severe plaque psoriasis.
However, most studies assessing its effectiveness in routine clinical settings in China are …

Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for
the treatment of moderate to severe psoriasis in September 2015. Objectives: To assess the …

To the Editor: Psoriasis is a chronic, recurrent, systemic, immune-mediated inflammatory
disease that mainly affects the skin, nails, and joints. Plaque psoriasis is the most common …

Background The efficacy and safety of secukinumab in patients with psoriasis has been
established in randomised clinical trials. However, data on effectiveness and safety of …

Background: There have been few real-life dose-comparing studies on the efficacy and
safety of secukinumab in Chinese patients with plaque psoriasis. We conducted a real-life …

Background: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the
Chinese population. Many patients are not well controlled by conventional treatments, thus …

Secukinumab, a fully human anti‐IL‐17A monoclonal antibody, neutralizes IL‐17A, a key
cytokine in the pathogenesis of psoriasis. Efficacy and safety of secukinumab was evaluated …

Introduction The association between physician-reported and patient-reported outcomes in
patients with psoriasis is not adequately explored. Trends in PASI scores across body …